Top news of the week: 10.08.2022.
“Bullish” Biopharma M&A Market Predicted for Closing Months of 2022
Subin Baral, EY Global Life Sciences Deals Leader, discusses current and projected short-term trends for biopharma M&A with GEN Edge.
Mathai Mammen makes an abrupt exit as head of the big R&D group at J&J
In an after-the-bell shocker, J&J announced Monday evening that Mathai Mammen has abruptly exited J&J as head of its top-10 R&D group. Recruited from Merck five years ago, where the ...
Do Q2 Results and Increased M&A Indicate a Recovery for Biotech?
A recent report predicts multiple acquisitions are set to be announced in the second half of the year, particularly by companies that have strong revenue streams from COVID-19 products.
Deal values top all recent years; M&As still in a slump
While biopharma M&As fail to keep up with prior years, the dealmaking environment remains strong, as deal values continue to grow. Through early August of this year, biopharma companies ...
Gilead Grabs MiroBio's Checkpoint Agonists For $405m
<p>Just over a month after raising $97m in a series B round, Oxford University spinout MiroBio and its immune checkpoint agonists have been snapped up by Gilead Sciences.<span> ...
Research Roundup: Why Kids Have More Protection Against COVID-19 & More
Covid-19, aging, stroke, ALS, colorectal cancers and Alzheimer's disease are all the focus of this week's top research stories.
Aug 2022: Bioprocessing Summit
KBI Biopharma will be at Bioprocessing Summit in Boston this August. We look forward to seeing you there!